N-of-1 Trials vs. Usual Care in Children With Hypertension: A Pilot Randomized Clinical Trial

被引:4
|
作者
Samuel, Joyce P. [1 ]
Bell, Cynthia S. [1 ]
Samuels, Joshua A. [1 ]
Rajan, Celin [2 ]
Walton, Adrienne K. [1 ]
Green, Charles [1 ]
Tyson, Jon E. [1 ]
机构
[1] UTHealth Houston, Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Dept Pediat, Houston, TX 77030 USA
[2] UTHealth Sch Publ Hlth, Houston, TX USA
关键词
blood pressure; hypertension; n; of; 1; trial; pediatric; personalized trial; single; patient multi; crossover trial; BLOOD-PRESSURE; ADOLESCENTS; CHILDHOOD; TIME;
D O I
10.1093/ajh/hpac117
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Background Blood pressure (BP) is often inadequately controlled in children treated for hypertension, and personalized (n-of-1) trials show promise for tailoring treatment choices. We assessed whether patients whose treatment choices are informed by an n-of-1 trial have improved BP control compared to usual care. Methods A randomized clinical trial was conducted in a pediatric hypertension clinic in Houston from April 2018 to September 2020. Hypertensive adolescents and young adults 10-22 years old were randomized 1:1 to a strategy of n-of-1 trial using ambulatory BP monitoring to inform treatment choice or usual care, with treatment selected by physician preference. The primary outcome was the proportion of patients with ambulatory BP control at 6 months in a Bayesian analysis. Results Among 49 participants (23 randomized to n-of-1 trials and 26 to usual care), mean age was 15.6 years. Using skeptical priors, we found a 69% probability that n-of-1 trials increased BP control at 6 months (Bayesian odds ratio (OR) 1.24 (95% credible interval (CrI) 0.51, 2.97), and 74% probability using neutral informed priors (OR 1.45 (95% CrI 0.48, 4.53)). Systolic BP was reduced in both groups, with a 93% probability of greater reduction in the n-of-1 trial group (mean difference between groups = -3.6 mm Hg (95% CrI -8.3, 1.28). There was no significant difference in side effect experience or caregiver satisfaction. Conclusions Among hypertensive adolescents and young adults, n-of-1 trials with ambulatory BP monitoring likely increased the probability of BP control. A large trial is needed to assess their use in clinical practice. ClinicalTrials.gov NCT03461003
引用
收藏
页码:126 / 132
页数:7
相关论文
共 50 条
  • [1] A Randomized Clinical Trial of n-of-1 Trials-Tribulations of a Trial
    Mirza, Reza D.
    Guyatt, Gordon H.
    JAMA INTERNAL MEDICINE, 2018, 178 (10) : 1378 - 1379
  • [2] Unblinded and Blinded N-of-1 Trials Versus Usual Care: A Randomized Controlled Trial to Increase Statin Uptake in Primary Care
    Tudor, Kate
    Brooks, Jenny
    Howick, Jeremy
    Fox, Robin
    Aveyard, Paul
    CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2022, 15 (06): : 393 - 402
  • [3] Treating Hypertension in Children With n-of-1 Trials
    Samuel, Joyce P.
    Tyson, Jon E.
    Green, Charles
    Bell, Cynthia S.
    Pedroza, Claudia
    Molony, Don
    Samuels, Joshua
    PEDIATRICS, 2019, 143 (04)
  • [4] A pilot study of ondansetron plus metopimazine vs. ondansetron monotherapy in children receiving highly emetogenic chemotherapy: a Bayesian randomized serial N-of-1 trials design
    Nathan, PC
    Tomlinson, G
    Dupuis, LL
    Greenberg, ML
    Ota, S
    Bartels, U
    Feldman, BM
    SUPPORTIVE CARE IN CANCER, 2006, 14 (03) : 268 - 276
  • [5] A pilot study of ondansetron plus metopimazine vs. ondansetron monotherapy in children receiving highly emetogenic chemotherapy: a Bayesian randomized serial N-of-1 trials design
    P. C. Nathan
    G. Tomlinson
    L. L. Dupuis
    M. L. Greenberg
    S. Ota
    U. Bartels
    B. M. Feldman
    Supportive Care in Cancer, 2006, 14 : 268 - 276
  • [6] N-of-1 Clinical Trials
    O'Connor, Christopher M.
    JACC-HEART FAILURE, 2019, 7 (07) : 630 - 631
  • [7] N-of-1 randomized controlled trials ('N-of-1 trials'): singularly useful in geriatric medicine
    Price, JD
    Evans, JG
    AGE AND AGEING, 2002, 31 (04) : 227 - 232
  • [8] N-of-1 Trials in Hypertension Are Feasible, but Are They Worthwhile?
    Kravitz, Richard L.
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2019, 34 (06) : 781 - 782
  • [9] N-of-1 Trials in Hypertension Are Feasible, but Are They Worthwhile?
    Richard L. Kravitz
    Journal of General Internal Medicine, 2019, 34 : 781 - 782
  • [10] A scoping review of randomized trials assessing the impact of n-of-1 trials on clinical outcomes
    Samuel, Joyce P.
    Wootton, Susan H.
    Holder, Travis
    Molony, Donald
    PLOS ONE, 2022, 17 (06):